Cardiac Myosin Activation for the Treatment of Systolic Heart Failure
Authors:
- 1 January 2021
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 77 (1) , 4-10
Abstract
Left ventricular systolic dysfunction is the hallmark pathology in heart failure with reduced ejection fraction. Increasing left ventricular contractility with beta-adrenergic receptor agonists, phosphodiesterase-3 inhibitors, or levosimendan has failed to improve clinical outcomes and, in some situations, increased the risk of sudden cardiac death. Beta-adrenergic receptor agonists and phosphodiesterase-3 inhibitors retain an important role in advanced heart failure. Thus, there remains an unmet need for safe and effective therapies to improve left ventricular systolic function. Two novel cardiac myotropes, omecamtiv mecarbil and danicamtiv, target cardiac myosin to increase left ventricular systolic performance. Neither omecamtiv mecarbil nor danicamtiv affects cardiomyocyte calcium handling, the proposed mechanism underlying the life-threatening arrhythmias associated with cardiac calcitropes and calcium sensitizers. Phase 2 clinical trials have demonstrated that these cardiac myosin activators prolong left ventricular systolic ejection time and promote left ventricular and atrial reverse remodeling. At higher plasma concentrations, these agents may be associated with myocardial ischemia and impaired diastolic function. An ongoing phase 3 clinical trial will estimate the clinical efficacy and safety of omecamtiv mecarbil. An additional study of these agents, which have minimal hemodynamic and renal effects, is warranted in patients with advanced heart failure refractory to guideline-directed neurohormonal blockers.Keywords
This publication has 25 references indexed in Scilit:
- Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjectsInt. Journal of Clinical Pharmacology and Therapeutics, 2016
- Structural basis for drug-induced allosteric changes to human β-cardiac myosin motor activityNature Communications, 2015
- Safety and Tolerability of Omecamtiv Mecarbil During Exercise in Patients With Ischemic Cardiomyopathy and AnginaJACC: Heart Failure, 2015
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive SummaryCirculation, 2013
- Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man studyThe Lancet, 2011
- The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trialThe Lancet, 2011
- Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart FailureScience, 2011
- Discovery ofOmecamtiv Mecarbilthe First, Selective, Small Molecule Activator of Cardiac MyosinACS Medicinal Chemistry Letters, 2010
- Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failureJACC, 2004